Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells

This Phase 1, open-label, non-randomized study will enroll pediatric and young adult subjects with relapsed or refractory non-central nervous system (CNS) malignant solid tumors expressing glypican-3 (GPC3) to examine the safety, feasibility, and efficacy of administering T cell products derived from peripheral blood mononuclear cells (PBMC) that have been genetically modified to co-express a GPC3-specific chimeric antigen receptor (CAR), interleukin (IL)-15 and IL-21 as well as the inducible caspase 9 (iC9) suicide gene (SC-CAR.GPC3xIL15.21 T cells). A child or young adult meeting all eligib

Trial Details

NCT ID

NCT07148050

Phase

PHASE1

Sponsor

Seattle Children's Hospital

Status

RECRUITING

Cancer Type

Kidney Cancer

Interventions

• SC-CAR.GPC3xIL15.21 CAR T cells

Locations (sample)

• Seattle, Washington, United States|47.60621,-122.33207

Key Eligibility Criteria

• Diagnosis of a solid tumor expressing GPC3
• Lansky or Karnofsky score of \>=60%
• Life expectancy of \>16 weeks
• Informed consent explained to, understood by and signed by patient/guardian.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →